Using denosumab and zoledronic acid to prevent bone loss after spinal cord injury
Denosumab and sequential zoledronic acid to prevent bone loss and maintain bone mass after spinal cord injury
This study is looking at how two medications, denosumab and zoledronic acid, can help prevent bone loss in people who have recently experienced a spinal cord injury, with the hope of improving their recovery and overall health.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University at Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-10854271 on NIH RePORTER |
What this research studies
This research focuses on preventing bone loss in individuals who have suffered an acute spinal cord injury (SCI) by using two medications: denosumab and zoledronic acid. The study aims to develop a detailed clinical trial plan that meets regulatory standards, which includes identifying clinical sites, creating training materials, and establishing data management protocols. The goal is to evaluate how effective these medications are in maintaining bone mass, particularly in the lower extremities, where significant bone loss occurs after SCI. By addressing the rapid bone loss that follows SCI, the research seeks to improve rehabilitation outcomes for affected individuals.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have recently experienced an acute spinal cord injury.
Not a fit: Patients who have not experienced a spinal cord injury or those with chronic conditions affecting bone health may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce the risk of fractures and improve rehabilitation opportunities for patients with spinal cord injuries.
How similar studies have performed: Previous small clinical trials have shown promising results for denosumab in preventing bone loss after spinal cord injury, indicating potential for success in this approach.
Where this research is happening
Chicago, United States
- Northwestern University at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Schnitzer, Thomas Jack — Northwestern University at Chicago
- Study coordinator: Schnitzer, Thomas Jack
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.